Amplifi Vascular is a clinical-stage medical device company developing the Amplifi Vein Dilation System for patients with end-stage kidney disease who need vascular access for hemodialysis. The system uses a wearable external blood pump with inflow and outflow catheters to rapidly enlarge forearm veins over several days before arteriovenous fistula (AVF) surgery. The device has received FDA Breakthrough Device designation and an Investigational Device Exemption, and the company launched its AMPLIFI-1 randomized pivotal trial after a 19-patient first-in-human study met its primary objectives. Amplifi Vascular was incorporated in December 2023 and is headquartered in Prairie Village, Kansas.